Mercury Pharmaceuticals

Incidence of ischemic cardio cerebrovascular disease rises among young women

Announcing a new article publication for Cardiovascular Innovations and Applications journal. The global burden, secular trends, and future projections of ischemic cardio-cerebrovascular disease (ICCVD), a composite indicator of ischemic heart disease (IHD) and ischemic stroke (IS), have not been specifically described in women.

New photoswitchable drugs restore light perception in blind animals

Blinding diseases caused by the degeneration of photoreceptors, such as age-related macular degeneration (AMD) and retinitis pigmentosa (RP), affect 200 million people worldwide and represent the leading causes of visual impairment and blindness.

Healthcare barriers impact survival rates for adult congenital heart disease

People with congenital heart disease living in states with low household incomes and limited access to health insurance and the specialized care they need may be more likely to become disabled or die from congenital heart disease, according to new, independent research published today in the Journal of the American Heart Association, an open-access, peer-reviewed journal of the American Heart Association.

AbbVie Strengthens Immunology Leadership with $10.9 Billion Apogee Therapeutics Acquisition

AbbVie's strategic acquisition of Apogee Therapeutics highlights its commitment to advancing immunology and developing next-generation treatments for patients.

Life sciences leaders face urgent workforce redesign challenge as AI reshapes productivity, skills and operating models

AI's impact on drug discovery and manufacturing raises critical workforce questions, driving life sciences organizations to rethink skills and leadership.

Europe’s fragmented early access landscape intensifies need for operational strategy ahead of the 5th Operationalise: Early Access Programmes Summit Europe

Join industry leaders at the 2026 summit to discuss strategies for navigating early access programmes and improving patient access to investigational therapies.

Thermo Fisher Scientific launches GENESYS™ G5 suite of spectrophotometers, combining UV-Vis performance with expandable software and workflow flexibility

Thermo Fisher Scientific has launched the Thermo Scientific™GENESYS™ G5 series of Visible and UV-Visible spectrophotometers, designed to help laboratories standardize workflows, simplify routine testing, and expand analytical capabilities as requirements evolve.

Breakthrough to give over 40,000 blind and low vision children access to coding

Study sheds light on the prognostic value of blood test for predicting cognitive impairment risk

A blood test for the biomarker phosphorylated tau 217 (p-tau217) recently received federal clearance, but questions have emerged around the extent to which such tests can accurately predict whether a cognitively healthy individual will go on to develop cognitive impairment-a key symptom of Alzheimer's disease.

Lack of awareness and healthcare barriers fuel perimenopause uncertainty

Perimenopause is an underrecognized life stage that is often accompanied by complex and fluctuating symptoms.